Clinical Trial

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-04-02; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-04-30
Trial Details
NCT Number NCT06920043
Lead Sponsor GlaxoSmithKline
Conditions Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Enrollment 42 participants
Start Date 2025-04-09
Primary Completion 2028-07-10 (estimated)
Study Completion 2028-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-08